Richard Lafayette, MD, FACP, Stanford University Medical Center, explains the significance of this second approval in a month ...

Novartis’ Vanrafia (atrasentan) has been granted accelerated approval by the US Food and Drug Administration (FDA) to treat ...

The FDA approved Novartis' Vanrafia® (atrasentan), a selective endothelin A receptor antagonist, for reducing proteinuria in adults with primary IgA nephropathy (IgAN) at risk of rapid disease ...

The FDA granted accelerated approval to atrasentan (Vanrafia) for the reduction of proteinuria in adults with primary immunoglobulin A (IgA) nephropathy, maker Novartis announced late on Wednesday.

The US FDA has granted accelerated approval to atrasentan (Vanrafia) for reducing proteinuria in adults with primary immunoglobulin A (IgA) nephropathy, according to an announcement by ...

"My son was diagnosed with IgA nephropathy long before there were ... care for this disease," said Victor Bultó, President, US, Novartis. "Building on our longstanding legacy in nephrology ...

"My son was diagnosed with IgA nephropathy long before there were ... care for this disease," said Victor Bultó, President, US, Novartis. "Building on our longstanding legacy in nephrology ...

Novartis has claimed accelerated approval from the FDA for Vanrafia, one of a trio of therapies it hopes will revolutionise the treatment of rare kidney disease IgA nephropathy (IgAN). Vanrafia ...

The FDA has granted accelerated approval to Vanrafia to reduce proteinuria in adults with primary IgAN at risk of rapid disease progression.

Novartis has claimed accelerated approval from the FDA for a second indication for Fabhalta – IgA nephropathy (IgAN) – as it charts a course to blockbuster sales for the drug. The US regulator ...